Ann Rheum Dis: Similar to Kawasaki disease, multisystem inflammatory syndrome in children associated with SARS-CoV-2 (Kawa-COVID-19)

Current data show that the prevalence of COVID-19 in children is low and the incidence is mildBut the number of children visiting hospitals in the greater Paris region in the past few weeks, similar to Kawasaki disease (KD), has increased, prompting the French national health authority to issue an alarmMulticenter editing (Kawa-COVID-19) was made to KD patients in the Paris region associated with the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since April 2020A "classic" KD historical queue is compared16 patients were included (sex ratio of 1, median age 10 years, IQR (4.7-12.5).)11 patients were tested for SARS-CoV-2 (69%), while another 5 patients reported recent exposure to quantitative PCR-positive individuals (31%)Heart conditioning included myocarditis in 44% of patients (n-7)The predictors of progress towards a serious disease (i.e., need ingestion in intensive care, n-7) are over 5 years of age and ferriteOnly 5 patients (31%) had successful treatment of immunoglobulin (IVIg), while 10 patients (62%) required second-line treatmentThe difference between the Kawa-COVID-19 queue and the "classic" KD control group is that the onset age is older (10 years vs 2 years old (p 0.0001) and the platelet count is low (188 vs 383G/L (p 0.0)" high incidence of myocarditis (7/16 vs 3/220 (p-0.001)) and first IVIg treatment resistance (10/16 vs 45/220 (p-0.004)Kawa-COVID-19 may represent a new systemic inflammatory syndrome that is time-related to SARS-CoV-2 infectionFurther prospective international studies are necessary to confirm these findings and better understand the pathophysiology of Kawa-COVID-19